Global Clinical Biomarkers Market: Focus on Product, Technology, End User, Clinical Area, Region, and Competitive Landscape – Analysis and Forecast, 2019-2029

Global Clinical Biomarkers Market: Focus on Product, Technology, End User, Clinical Area, Region, and Competitive Landscape – Analysis and Forecast, 2019-2029

  • March 2020 •
  • 213 pages •
  • Report ID: 5881507 •
  • Format: PDF
Global Clinical Biomarkers Market to Reach $45.91 Billion by 2029

Key Questions Answered in this Report:
• What are the major market drivers, challenges, and opportunities in the global clinical biomarkers market?
• What are the key development strategies which are implemented by the major players in order to sustain in the competitive market?
• What are the key technologies that have been used by leading players in the market for the development of biomarkers-based assays?

• How each segment of the market is expected to grow during the forecast period from 2019 to 2029 based on:
o Product type
o Clinical area
o Technology
o End user
o Region: Region includes North America, Europe, Asia-Pacific, Rest-of-the-World (ROW)
• Who are the leading players with significant offerings to the global clinical biomarkers market? What is the expected market dominance for each of these leading players?
• Which companies are anticipated to be highly disruptive in the future and why?

Global Clinical Biomarkers Market, 2019-2029

Global clinical biomarkers market analysis projects the market to grow at a significant CAGR of 10.07% during the forecast period, 2019-2029. Global clinical biomarkers market generated $16.01 billion revenue in 2018, in terms of value.

The growth in global clinical biomarkers market is anticipated to be driven by increasing prevalence of infectious diseases, increase in adoption of personalized medicine, growing focus on biomarker research and development programs and rising demand for non-invasive diagnosis.However, there are potential restraining factors hindering the growth of the market.

These factors include uncertain reimbursement policies pertaining to clinical biomarkers-based products, requirement of high capital investment, and issues related to clinical validity of biomarkers.

Expert Quote

“Efficient translation of MS-based biomarker discovery research into the development of routine clinical diagnostic assays is an important challenge in the field of personalized medicine.”

Scope of the Market Intelligence on Global Clinical Biomarkers Market

Global clinical biomarkers market research provides a holistic view of the market in terms of various factors influencing it, including strategic developments and technological advancements.

The scope of this report is centered upon conducting a detailed study of the products and manufacturers allied with the industrial and biological research. In addition, the study also includes exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of leading manufacturers, growth potential of each underlying sub-segment, and company, as well as other vital information with respect to global clinical biomarkers market.

Market Segmentation

Global clinical biomarkers market (on the basis of type) is segmented into diagnostic, prognostic and predictive biomarkers.

Global clinical biomarkers market (on the basis of clinical area) is segmented into cancer biomarkers, cardiac biomarkers, neurological biomarkers, infectious disease, immunological biomarkers, non-invasive prenatal testing and other clinical areas.

Global clinical biomarkers market (on the basis of technology) is segmented into real-time polymerase chain reaction, next-generation sequencing, Enzyme-linked immunosorbent assay (ELISA), and other technologies.

Global clinical biomarkers market (on the basis of end user) is segmented into research and academic laboratories, diagnostic centers, biopharmaceutical and biotech companies and other end users.

Key companies in the Global Clinical Biomarkers Market

The report also comprises 15 detailed company profiles including several key players, such as Abbott Laboratories, Agilent Technologies, Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, Myriad Genetics, Hologic, Inc., Bio-Rad Laboratories, Inc., Qiagen N.V., Enzo Biochem Inc., Centogene N.V., ALCEDIAG, and Quest Diagnostics Incorporated.

Countries Covered
• North America
• U.S.
• Canada
• Europe
• Germany
• U.K.
• France
• Italy
• Spain
• Rest-of-Europe
• Asia-Pacific
• China
• Japan
• India
• Australia
• Singapore
• Rest-of-Asia-Pacific
• Latin America
• Brazil
• Mexico
• Rest-of-Latin America
• Rest-of-the-World